Back

Wearable neuroprosthesis improves mobility and reduces pain in neuropathic participants

Gozzi, N.; Chee, L.; Odermatt, I.; Kikkert, S.; Preatoni, G.; Valle, G.; Pfender, N.; Beuschlein, F.; Wenderoth, N.; Zipser, C. M.; Raspopovic, S.

2024-05-09 endocrinology
10.1101/2024.05.08.24306164 medRxiv
Show abstract

Peripheral neuropathy (PN) is the most common complication of diabetes. It is characterized by sensory loss which often causes major health consequences including foot ulceration, chronic pain, poor mobility and increased risk of falls. However, present treatments do not counteract the cause of the disease, namely lack of sensory feedback, but rather aim at partial and temporal symptoms relief (e.g. analgesics for pain or creams for ulcers healing). Electrical stimulation is a promising solution for sensory restoration, but it is yet unknown if it can elicit perceivable sensations in PN damaged nerves and whether it could lead to any health or functional benefits. To this aim, we designed a wearable sensory neuroprosthesis providing targeted neurostimulation at the ankle level (NeuroStep) restoring feet lost sensations. We tested it in 14 participants with PN, evaluating its effects on functional outcomes and pain, and the cortical activation related to the restored sensations. Our system was able to restore lost sensations in all participants. The nerves of PN participants resulted significantly less excitable and sensitive than healthy individuals (N=22). Thanks to the neurostimulation, participants improved cadence and functional gait, with even stronger improvements in individuals with higher risk of falls. A full day of NeuroStep use led to a clinically significant reduction of 30.4% {+/-} 9.2% in neuropathic pain. Restored sensations activated cortical patterns, as measured via fMRI, similar to the naturally located foot sensations, thus not requiring training by the user. NeuroStep restores intuitive sensations in PN participants, improving mobility and decreasing pain, possibly replacing multiple inefficient treatments. It holds potential to drastically improve patients quality of life thanks to functional and health benefits, while paving the way to new effective neuromodulation treatments.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

1
Advanced Science
249 papers in training set
Top 0.1%
49.1%
2
Scientific Reports
3102 papers in training set
Top 8%
9.4%
50% of probability mass above
3
Nature Communications
4913 papers in training set
Top 35%
4.3%
4
Frontiers in Physiology
93 papers in training set
Top 2%
2.8%
5
PLOS ONE
4510 papers in training set
Top 44%
2.7%
6
Journal of Neural Engineering
197 papers in training set
Top 0.9%
2.1%
7
Bioengineering
24 papers in training set
Top 0.3%
1.9%
8
Journal of Visualized Experiments
30 papers in training set
Top 0.2%
1.8%
9
IEEE Transactions on Neural Systems and Rehabilitation Engineering
40 papers in training set
Top 0.3%
1.7%
10
IEEE Journal of Biomedical and Health Informatics
34 papers in training set
Top 1.0%
1.7%
11
iScience
1063 papers in training set
Top 14%
1.7%
12
eLife
5422 papers in training set
Top 45%
1.5%
13
Sensors
39 papers in training set
Top 1%
1.3%
14
Nature Biomedical Engineering
42 papers in training set
Top 2%
0.8%
15
Journal of NeuroEngineering and Rehabilitation
28 papers in training set
Top 0.9%
0.8%
16
Brain Stimulation
112 papers in training set
Top 1%
0.7%
17
Biomedicines
66 papers in training set
Top 3%
0.7%
18
Frontiers in Bioengineering and Biotechnology
88 papers in training set
Top 3%
0.7%
19
PeerJ
261 papers in training set
Top 15%
0.7%
20
Biosensors and Bioelectronics
52 papers in training set
Top 1%
0.7%
21
JMIR Public Health and Surveillance
45 papers in training set
Top 4%
0.7%
22
Cell Reports Physical Science
18 papers in training set
Top 1%
0.7%
23
Human Brain Mapping
295 papers in training set
Top 5%
0.7%
24
European Respiratory Journal
54 papers in training set
Top 2%
0.5%
25
npj Digital Medicine
97 papers in training set
Top 4%
0.5%
26
Heliyon
146 papers in training set
Top 9%
0.5%